Skip to main content
Equibles
SLS logo

SLS · SELLAS Life Sciences Group, Inc.

Track SLS — free

Use SLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.61 +0.35 (+3.11%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.27B
Shares
201.95M
Volume · Oct 9 1.69M Avg daily vol (3M) 6.53M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.26 Open$11.17 Day$10.71–11.34 52W close$1.39–15.46 Avg vol 30d6.3M Short int59.1M · 29.2% float · 8.6d Short vol60% Last earningsMay 27, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 11

Up next

Next earnings call
May 26, 2027 Est · unconfirmed · in 33 wks
Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$32.46M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+92.0%
Year over year · more shares
Price change (1Y)
+483.4%
Trailing year
Short interest
29.2%
Latest settlement · 8.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +41%
above
Price vs 50-day avg −9%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 70%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −17%
trailing
6-month return +116%
trailing
YTD return +199%
this year
Relative strength +107%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $8 — 50d above 200d
Institutional flow Distributing
8 of 208 funds reported for Sep 30 · net -46.0K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
29.25% of float · ▲ +2.0% MoM · 8.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
208 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +50%
Y/Y
Free cash flow $-28.4M
Balance sheet $5.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 106%
annualized · 1-yr
Max drawdown −36%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+41% Bullish
Price vs 50-day avg
−9% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
70% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $8 — 50d above 200d
Institutional flow Distributing
8 of 208 funds reported for Sep 30 · net -46.0K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
29.25% of float · ▲ +2.0% MoM · 8.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
208 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $11 · 70% Range high $15
vs 200-day avg +41% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLS
SELLAS Life Sciences Group, Inc.
this stock
$2.27B +198.7% -100.0% — 29.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +11.0% +46.2% 29.3 1.9%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.5%
CSLLY
Csl Ltd
 $60.24B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
209
% held
51.3%
Reported
8 of 208
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
124
View
Short & Settlement
Short Interest Rising
Shares short
59.1M
Days to cover
8.6d
Change
+1.1M sh
View
Short Volume
Short vol %
60%
As of
Oct 8, 2026
Short Total
View
Fails to Deliver
FTD shares
990
Value
$11.4K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
53.2%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-26.9M
EPS diluted
$-0.25
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
13
View
Exempt Offerings
Offering
$18.4M
Filed
Mar 29, 2024
View
Earnings & Events
Webcasts
Last webcast
Sep 28, 2026
View

Performance

5D 20D 120D MTD YTD
SLS -0.6% -16.5% +115.7% -8.5% +198.7%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -1.9% -18.7% +106.7% -10.0% +185.2%
Key facts CIK 1390478 CUSIP 81642T209 13F (30d) 11 filings 11 filers Visit website Investor relations